Insider Buying: Tharimmune, Inc. (NASDAQ:THAR) COO Acquires 5,000 Shares of Stock

Tharimmune, Inc. (NASDAQ:THAR) COO Sireesh Appajosyula purchased 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were acquired at an average price of $2.02 per share, for a total transaction of $10,100.00. Following the completion of the acquisition, the chief operating officer now directly owns 10,758 shares in the company, valued at approximately $21,731.16. This represents a 86.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Sireesh Appajosyula also recently made the following trade(s):

• On Tuesday, October 8th, Sireesh Appajosyula bought 5,000 shares of Tharimmune stock. The shares were bought at an average price of $1.93 per share, for a total transaction of $9,650.00.

Tharimmune Stock Performance

NASDAQ:THAR opened at $2.23 on Friday. The firm has a fifty day simple moving average of $2.47 and a two-hundred day simple moving average of $3.39. Tharimmune, Inc. has a 12 month low of $1.84 and a 12 month high of $79.65.

Institutional Investors Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune at the end of the most recent reporting period. Institutional investors and hedge funds own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).